These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 8309173

  • 41. Electrical effects of the new antiarrhythmic compound Bonnecor (AWD 19-166, GS 015) under arrhythmogenic conditions.
    Nilius B.
    Pharmazie; 1985 Dec; 40(12):855-6. PubMed ID: 3841602
    [Abstract] [Full Text] [Related]

  • 42. Use dependent depression of fast sodium current in heart muscle by the new antiarrhythmic substance Bonnecor (AWD 19-166, GS 015).
    Nilius B, Benndorf K, Schüttler K, Boldt W.
    Pharmazie; 1985 Dec; 40(12):852-4. PubMed ID: 2419929
    [Abstract] [Full Text] [Related]

  • 43. New data on the antiarrhythmic value of parenteral magnesium treatment: magnesium and ventricular arrhythmias.
    Perticone F, Ceravolo R, De Novara G, Torchia L, Cloro C.
    Magnes Res; 1992 Dec; 5(4):265-72. PubMed ID: 1296762
    [Abstract] [Full Text] [Related]

  • 44. [Comparative study of the effectiveness of Bonnecor and ethacizine in various disorders of cardiac rhythm].
    Tatarchenko IP, Ermolaeva NN, Oleĭnikov VE, Perevarin AV, Rakhmatullov FK.
    Klin Med (Mosk); 1991 Aug; 69(8):60-2. PubMed ID: 1724273
    [Abstract] [Full Text] [Related]

  • 45. CL-845 (pirmenol hydrochloride): a new orally effective long-acting antiarrhythmic agent.
    Steffe TJ, Mertz TE, Hastings SG, Potoczak RE, Kaplan HR.
    J Pharmacol Exp Ther; 1980 Jul; 214(1):50-7. PubMed ID: 7391970
    [No Abstract] [Full Text] [Related]

  • 46. [The effect of disopyramide, mexiletine and propafenon after intravenous and oral administration on left ventricular function in the M-mode echocardiogram].
    Böcker K, Köhler E, Seipel L, Loogen F.
    Z Kardiol; 1982 Dec; 71(12):839-45. PubMed ID: 7164536
    [Abstract] [Full Text] [Related]

  • 47. [Characteristics of the anti-arrhythmic action of 3-carbethoxyamino-5-dimethylaminoacetyl-imino-dibenzyl hydrochloride (Bonnecor, AWD 19-166, GS 015)].
    Kaverina NV, Berdjajev SJ, Darinskij NV.
    Pharmazie; 1985 Dec; 40(12):840-4. PubMed ID: 3841598
    [Abstract] [Full Text] [Related]

  • 48. [Electrophysiological anti-arrhythmia effects of tiracizine in ventricular tachycardia].
    Volkmann H, Kühnert H, Dannberg G, Heinke M, Leeder U, Popp U.
    Z Gesamte Inn Med; 1991 Dec; 46(17):635-41. PubMed ID: 1776306
    [Abstract] [Full Text] [Related]

  • 49. [The pharmacology of the new combined anti-arrhythmia preparation metatsizin].
    Kaverina NV, Chichkanov GG, Bugriĭ EM, Vititnova MB, Tolmacheva EA, Turilova AI, Kryzhanovskiĭ SA, Lyskovtsev VV, Rodionov AP, Beloborodov VL.
    Eksp Klin Farmakol; 1998 Dec; 61(2):33-6. PubMed ID: 9621171
    [Abstract] [Full Text] [Related]

  • 50. [Initial results of clinical research on a tabletted form of ethacizin (the diethylamino analog of ethmozine) in ventricular arrhythmias].
    Rozenshtraukh LV, Shugushev KhKh, Smetnev AS, Mukharliamov NM, Ponomarenko EL.
    Kardiologiia; 1985 Mar; 25(3):43-50. PubMed ID: 2582177
    [Abstract] [Full Text] [Related]

  • 51. Oral flecainide acetate for the treatment of ventricular arrhythmias.
    Anderson JL, Stewart JR, Perry BA, Van Hamersveld DD, Johnson TA, Conard GJ, Chang SF, Kvam DC, Pitt B.
    N Engl J Med; 1981 Aug 27; 305(9):473-7. PubMed ID: 7019711
    [Abstract] [Full Text] [Related]

  • 52. [Effect of ethacizine on the heart conduction system and the indicators of central hemodynamics].
    Gorshkov VA, Nesvetov VN, Kesarev GV, Sherashov VS, Mamaev VI.
    Sov Med; 1991 Aug 27; (8):9-11. PubMed ID: 1763379
    [Abstract] [Full Text] [Related]

  • 53. Electrophysiological effects of a new antiarrhythmic substance Bonnecor (AWD 19-166, GS 015) on mammalian myocardium.
    Nilius B, Schüttler K, Benndorf K, Boldt W.
    Pharmazie; 1985 Dec 27; 40(12):847-51. PubMed ID: 3841600
    [Abstract] [Full Text] [Related]

  • 54. [Comparative clinical study of the effectiveness of the new anti-arrhythmia agents, trimecaine and pyrromecaine].
    Pavlova TS, Riabokon' OS, Ivanova LA, Sumarokov AB.
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1983 Dec 27; 6(2):67-72. PubMed ID: 6196040
    [Abstract] [Full Text] [Related]

  • 55. [Digoxin in the treatment of patients with ventricular disorders of cardiac rhythm].
    Kurbanov RD, Kiiakbaev GK, Khodzhanova TR.
    Kardiologiia; 1985 Jul 27; 25(7):74-7. PubMed ID: 2414507
    [Abstract] [Full Text] [Related]

  • 56. [Clinical experiences with a new orally effective antiarrhythmic agent (Aprindin)].
    Breithardt G, Gleichmann U, Seipel L, Loogen F.
    Z Kardiol; 1974 May 27; 63(3):435-44. PubMed ID: 4608660
    [No Abstract] [Full Text] [Related]

  • 57. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T, Groysman R, Meilichov I.
    Pharmacotherapy; 2008 Jan 27; 28(1):14-9. PubMed ID: 18154469
    [Abstract] [Full Text] [Related]

  • 58. [Effect of using a mexitil preparation in cardiac rhythm disorders].
    Dimitrov D, Dzhurdzhev A, Batalov Z.
    Vutr Boles; 1981 Jan 27; 20(1):71-5. PubMed ID: 7245728
    [Abstract] [Full Text] [Related]

  • 59. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
    Stambler BS, Gottlieb SS, Singh BN, Ramanathan KB, Ogilby JD, Ellenbogen KA.
    J Am Coll Cardiol; 1995 Dec 27; 26(7):1679-84. PubMed ID: 7594103
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.